Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Venous Thromboembolism and Major Bleeding in Patients With Coronavirus Disease 2019 (COVID-19): A nationwide population-based cohort study

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Efficacy, immunogenicity, and evidence for best-timing of pneumococcal vaccination in splenectomized adults: a systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Socioeconomic functioning in patients with brain abscess - a nationwide, population-based cohort study in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Risk factors for fatigue and impaired function eight months after hospital admission with COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Venous thromboembolism (VTE) is a potentially fatal complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and thromboprophylaxis should be balanced against risk of bleeding. This study examined risks of VTE and major bleeding in hospitalized and community-managed SARS-CoV-2 patients compared with control populations.

METHODS: Using nationwide population-based registries, 30-day risks of VTE and major bleeding in SARS-CoV-2 positive patients were compared with those of SARS-CoV-2 test-negative patients and with an external cohort of influenza patients. Medical records of all COVID-19 patients at 6 departments of infectious diseases in Denmark were reviewed in detail.

RESULTS: The overall 30-day risk of VTE was 0.4% (40/9460) among SARS-CoV-2 patients (16% hospitalized), 0.3% (649/226 510) among SARS-CoV-2 negative subjects (12% hospitalized), and 1.0% (158/16 281) among influenza patients (59% hospitalized). VTE risks were higher and comparable in hospitalized SARS-CoV-2 positive (1.5%), SARS-CoV-2 negative (1.8%), and influenza patients (1.5%). Diagnosis of major bleeding was registered in 0.5% (47/9460) of all SARS-CoV-2 positive individuals and in 2.3% of those hospitalized. Medical record review of 582 hospitalized SARS-CoV-2 patients observed VTE in 4% (19/450) and major bleeding in 0.4% (2/450) of ward patients, of whom 31% received thromboprophylaxis. Among intensive care patients (100% received thromboprophylaxis), risks were 7% (9/132) for VTE and 11% (15/132) for major bleeding.

CONCLUSIONS: Among people with SARS-CoV-2 infection in a population-based setting, VTE risks were low to moderate and were not substantially increased compared with SARS-CoV-2 test-negative and influenza patients. Risk of severe bleeding was low for ward patients, but mirrored VTE risk in the intensive care setting.

Original languageEnglish
Article numberciab003
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Issue number12
Pages (from-to)2283-2293
Number of pages11
Publication statusPublished - 16 Dec 2021

    Research areas

  • Anticoagulants, COVID-19, Cohort Studies, Hemorrhage/epidemiology, Humans, SARS-CoV-2, Venous Thromboembolism/epidemiology, bleeding, venous thromboembolism, deep venous thrombosis, pulmonary embolism, hemorrhage

ID: 61650577